PCSK9 inhibitors shine at AHA, but how to differentiate?
This article was originally published in Scrip
Phase III results for the PCSK9 inhibitor alirocumab from Regeneron Pharmaceuticals and partner Sanofi and their competitor Amgen's evolocumab show remarkable reductions in LDL-cholesterol (LDL-c) levels, but the similar body of data for both biologics make it difficult to guess which therapy will come out on top as they edge closer to US FDA approval in 2015.
You may also be interested in...
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.